Related Experiment Videos
Graft-versus-host disease after marrow transplantation
Progress in Clinical and Biological Research
|January 1, 1986
Summary
Graft-versus-host disease (GVHD) remains a challenge in marrow transplantation. Combining cyclosporine with methotrexate shows promise in reducing GVHD and improving survival in dogs and humans.
Area of Science:
- Immunology
- Transplantation Medicine
- Hematology
Background:
- Graft-versus-host disease (GVHD) occurs in 30-50% of marrow transplant recipients despite immunosuppression.
- Current immunosuppressive drugs like methotrexate and cyclosporine have limitations in efficacy and side effects.
Purpose of the Study:
- To evaluate the efficacy of combining methotrexate and cyclosporine for GVHD prevention and treatment.
- To investigate the role of T cells in the pathogenesis of acute and chronic GVHD.
- To explore alternative donor sources for marrow transplantation.
Main Methods:
- Controlled trials comparing immunosuppressive drugs.
- Canine models to test combined immunosuppression regimens.
- Analysis of T cell responses in canine and human chimeras.
- Studies on partially matched related and unrelated donor transplants.
Main Results:
- Combining methotrexate with cyclosporine reduced GVHD incidence and improved survival in canine models and early human trials.
- T cells play a direct pathogenic role in GVHD.
- Removal of donor T cells reduces acute GVHD but increases graft failure risk.
- Chronic GVHD affects ~40% of recipients, particularly older patients, and is difficult to treat.
- Transplants from partially matched donors increase GVHD, with survival influenced by patient age and disease status.
Conclusions:
- Combined methotrexate and cyclosporine therapy is a promising strategy for mitigating GVHD and enhancing survival.
- Targeting T cell-mediated immunity is crucial for GVHD management.
- Further research into donor selection and GVHD prevention is warranted for improving transplant outcomes.